Three things to know:
1. The study will enroll 320 people aged 30 to 70 years old who have been diagnosed with leg pain from a herniated lumbar disc.
2. A Phase 3 study in Japan demonstrated that an injection of the drug into the nucleus pulposus reduced nerve root by decreasing pressure and volume of herniation, resulting in less pain.
3. SI-6603, the study drug, has yet to be approved for use in the U.S. by the FDA.
More articles on spine:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
